

## REFERENCES

### A

- Albers, E., Müller, B.W., 1995. Cyclodextrin derivatives in pharmaceuticals. *Crit. Rev. Therap. Drug. Carrier. Syst.* 12, 311-337.
- Alexishvili M.M., Rukhadze M.D., Okujava V.M., 1997. Simultaneous determination of carbamazepine and carbamazepine 10,11-epoxide by using microcolumn HPLC: study of pharmacokinetics of carbamazepine in a volunteer, *Biomed. Chromatograph.* 11, 36-41.
- Aliza R., Tzviel S., Lev B., Abraham D.J., 2002. Phospholipid coated poly(lactic acid) microspheres for the delivery of LHRH analogues. *Polymer for Adv. Tech.* 13(2), 127-136.
- Amorim M.J., Ferreira J.P., 2001. Microparticles for delivering therapeutic peptides and proteins to the lumen of the small intestine. *Eur. J. Pharm. Sci.* 52, 39-44.
- Andrianov A.K., Payne L.G., 1998. Polymeric carriers for oral uptake of microparticulates. *Adv. Drug Deliv. Rev.* 34, 155-170.
- Arangoa M.A., Campanero M.A., Renedo M.J., Ponchel G., and Irache J.M., 2001. Gliadin nanoparticles as carriers for the oral administration of lipophilic drugs. Relationships between bioadhesion and pharmacokinetics. *Pharm. Res.* 18, 1521-1527.
- Athanasiou K.A., Niederauer G.G., Agrawal C.M., 1996. Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/polyglycolic acid copolymers. *Biomaterials* 17, 93-102.
- Attia M.A., Habib F.S., 1985. Dissolution rates of carbamazepine and nitrazepam utilizing sugar solid dispersion system. *Drug Dev. Ind. Pharm.* 11, 1957-1969.

### B

- Bahl B.S., Tuli G.D., Bahl A., 1997. Essentials of physical chemistry. pp 343-345. S. Chand Company LTD.
- Bailey J.W., Haymond M.W., Miles J.M., 1991. Triacetin: a potential parenteral nutrient. *JPEN J Parenter. Enteral. Nutr.* 15, 32-36.
- Bakatselou V., Oppenheim R.C., Dressman J.B., 1991. Solubilization and wetting effects of bile salts on the dissolution of steroids. *Pharm. Res.* 8, 1461-1469.
- Barton A.F.M., 1983. CRC Handbook of solubility parameters and other cohesion parameters. CRC press: Boca Raton, FL.

- Baughman R.A., Kapoor S.C., Agarwal R.K., Kisicki J., Catella-Lawson F., Fitzgerald G.A., 1998. Oral delivery of anticoagulant doses of heparin. A randomized, double-blinded controlled study in humans. *Circulation* 98, 1610-1615.
- Behme R. J., Brooke D., 1991. Heat of fusion measurement of a low melting polymorph of carbamazepine that undergoes multiple phase changes during differential scanning calorimetry analysis. *J. Pharm. Sci.* 80, 986-990.
- Bertilsson L., 1978. Clinical pharmacokinetics of carbamazepine. *Clin. Pharmacokinet.* 3, 128-143.
- Betageri G.V., Makarla K.R., 1995. Enhancement of dissolution of glyburide by solid dispersion and lyophilization techniques. *Int. J. Pharm.* 126, 155-160.
- Bhagwatwar H.P., Bapat V.R., Paithankar M.B., Yeola B.S., Gosavi A.S., Bagoool M.A., Shetty D.N.J., Chaturvedi N.C., Beri S., 2003. Novel in-situ forming controlled release microcarrier delivery system. US patent, 424/486.
- Bibby D.C., Davies N.M., Tucker I.G., 2000. Mechanisms by which cyclodextrins modify drug release from polymeric drug delivery systems. *Int. J. Pharm.* 197, 1-11.
- Bodmeier R., 1997. Verfahren zur in-situ Herstellung von Partikeln. *Offenlegungsschrift*, DE 197 24 784.
- Bodmeier R., McGinity J.W., 1987. Polyactic acid microspheres containing quinidine base and quinidine sulphate prepared by the solvent evaporation technique. I. Methods and morphology. *J. Microencapsul.* 4, 279-288.
- Brennan T.V., Clarke S., 1993. Spontaneous degradation of polypeptides at aspartyl and asparaginyl residues: effects of the solvent dielectric. *Protein Science* 2, 331-338.
- Brodbeck K.J., Gaynor-Duarte A.T., Shen T.T.I., 2004. Gel composition and methods. US Patent 6,673,767.
- Brodbeck K.J., Prestrelski S.J., Pushpala S.J., 2000. Implantable gel compositions and method of manufacture. WO 00/74650 A2.
- Brodbeck K.J., Pushpala S., McHugh A.J., 1999. Sustained release of human growth hormone from PLGA solution depots. *Pharm. Res.* 16 (12), 1825-1829.
- Brodbeck K.J., Shen T.T., 1998. Injectable depot gel composition and method of preparing the composition. WO 98/27962.

## C

- Cai Q., Bei J., Luo A., Wang S., 2001. Biodegradation behaviour of poly(lactide-co-glycolide) induced by microorganisms. *Polymer degradation and stability* 71, 243-251.

- Carraway K.M., Sullivan S.A., Gibson J.W., Tipton A.J., 1999. Oral controlled release of antiretrovirals using the SABER delivery system incorporated into soft gelatin capsules. 14th Meeting of the American Association of Pharm. Scientists AAPS, PharmSci Supplement 17, 439.
- CD Cydex, 2003. Captisol<sup>®</sup> : A reality in commercial formulation. [www.captisol.com](http://www.captisol.com).
- CDER. Guidance for Industry Q3C Impurities: Residual Solvents. <http://www.fda.gov/cder/guidance/Q3Cfinal.htm>.
- Cha Y., Pitt C.G., 1990. The biodegradability of polyester blends. *Biomaterials* 11, 108-112.
- Challacombe S.J., Rahman D., Jeffery H., Davis S.S., O'Hagan D.T., 1992. Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen. *Immunology* 76(1), 164-168.
- Chandrashekar G., Udupa N., 1996. Biodegradable injectable implant systems for long term drug delivery using poly(lactic-co-glycolic) acid copolymers. *J. Pharm. Pharmacol.* 48, 669-74.
- Chen X., Young T.J., Sarkari M., Williams R.O., Johnston K.P., 2002. Preparation of cyclosporine A nanoparticles by evaporative precipitation into aqueous solution. *Int. J. Pharm.* 242, 3-14.
- Chern R.T., Zingerman J.R., 2004. Liquid polymeric compositions for controlled release of bioactive substances. US Patent 6,733,767.
- Chiou W.L., Riegelman S., 1971. Pharmaceutical applications of solid dispersions. *J. Pharm. Sci.* 60, 1281-1302.
- Choi H.G., Kim D.D., Jun H.W., Yoo B.K., Yong C.S., 2003. Improvement of dissolution and bioavailability of nitrendipine by inclusion in hydroxypropyl-beta-cyclodextrin. *Drug Dev. Ind. Pharm.* 29(10), 1085-94.
- Chourasia M.K., Jain S.K., 2003. Pharmaceutical approaches to colon targeted drug delivery systems. *J. Pharm. Pharmaceut. Sci.* 6(1), 33-66.
- Chung T.W., Huang Y.Y., Liu Y.Z., 2001. Effects of the rate of solvent evaporation on the characteristics of drug loaded PLLA and PDLLA microspheres. *Int. J. Pharm.* 212, 161-169.
- Cleland J.L., Johnson O.L., Putney S., Jones A.J.S., 1997. Recombinant human growth hormone poly(lactic-co-glycolic acid) microsphere formulation development. *Adv. Drug Deliv. Rev.* 28, 71-84.
- Craig D.Q.M., 2002. The mechanisms of drug release from solid dispersions in water-

soluble polymers. *Int. J. Pharm.* 203, 131-144.

## D

De Jaeghere F., Allemann E., Doelker E., and Gurry R., 2001. pH-dependent dissolving nano- and microparticles for improved peroral delivery of a highly lipophilic compound in dogs. *AAPS Pharmsci* 3 (1) article 8.

De Jaeghere F., Allemann E., Kubel F., Galli B., Cozen R., Doelker E., and Gurny R., 2000. Oral bioavailability of a poorly water soluble HIV-1 protease inhibitor incorporated into pH-sensitive particles: effect of the particle size and nutritional state. *J. Control. Rel.* 68, 291-29.

Degussa, Röhm Pharma Polymers. Enteric coating with EUDRAGIT® L/S from aqueous dispersion. Tablets coated with redispersed EUDRAGIT® L/S 100. [http://www.roehm.de/en/pharmapolymers?content=/en/pharmapolymers/formulation/enteric/enteric\\_app](http://www.roehm.de/en/pharmapolymers?content=/en/pharmapolymers/formulation/enteric/enteric_app).

Delgado A., Lavelle E.C., Hartshorne M., Davis S.S., 1999. PLG microparticles stabilized using enteric coating polymers as oral vaccine delivery systems. *Vaccine* 17(22), 2927-2938.

Desai M.P., Labhasetwar V., Amidon G.L., Levy R.J., 1996. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. *Pharm. Res.* 13(12), 1838-1845.

Desai M.P., Labhasetwar V., Walter E., Levy R.J., Amidon G.L., 1997. The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. *Pharm. Res.* 14(11), 1568-1573.

Dittgen M., Fricke S., Gerecke H., Osterwald H., 1995. Hot spin mixing: a new technology to manufacture solid dispersion-part 1: testosterone. *Pharmazie* 50, 225-226.

Dollo G., Le Corre P., Guerin A., Chevanne F., Burgot J.L., Leverage R., 2003. Spray-dried redispersible oil-in-water emulsion to improve oral bioavailability of lipophilic drugs. *Eur. J. Pharm. Sci.* 19(4), 273-280.

Drewe J., Beglinger C., Kissel T., 1992. The absorption site of cyclosporin in the human gastrointestinal tract. *Br. J. Clin. Pharmacol.* 33, 39-43.

Dunn R.L., English D.R., Cowsar D.R., Vanderbilt D.P., 1990. Biodegradable in-situ forming implants and methods of producing the same. US Patent 4,938,763.

Dunn R.L., English J.P., 2003. Biodegradable polymer composition. US Patent 6,528,080.

- Dunn R.L., English J.P., Cowsar D.R., Vanderbilt D.P., 2002. Biodegradable in-situ forming implants and methods of producing the same. US Patent RE37, 950.
- Dunn R.L., Garrett J.S., Ravivarapu H., Chandrashekar B.L., 2004. Polymeric delivery formulations of leuprolide with improved efficacy. US Patent 6,773,714.
- Dunn R.L., Tipton A.J., Southard G.L., Rogers J.A., 1991. Biodegradable system for regenerating the periodontium. US Patent 5,077,049.
- Dunn R.L., Tipton A.J., Southard G.L., Rogers J.A., 1994. Biodegradable system for regenerating the periodontium. US Patent 5,368,859.
- Dunn R.L., Tipton A.J., Southard G.L., Rogers J.A., 1997. Biodegradable polymer composition. US Patent 5,599, 552.
- Dunne M., Corrigan O.I., Ramtoola Z., 2000. Influence of particle size and dissolution conditions on the degradation properties of polylactide-co-glycolide particles. *Biomaterials* 21, 1659-1668.

## **E**

- Eliasz, Rom, Kost, Joseph, 2001. Composition and method for forming biodegradable implants in situ and uses of these implants. US Patent 6,206,920.
- El-Zein H., Riad L., El-Bary A.A., 1998. Enhancement of carbamazepine dissolution: in vitro and in vivo evaluation. *Int. J. Pharm.* 168, 209-220.
- EMEA/MRL/457/98-final, 1998. Committee for veterinary medical products, 2-pyrrolidone, summary report. The European agency for the evaluation of medical products, veterinary medicines evaluation unit.

## **F**

- Fahr A., 1993. Cyclosporin clinical pharmacokinetics. *Clin. Pharmacokinet.* 24, 472-495.
- Fessi H., Puisieux F., Devissaguet J.P., Ammoury N., Benita S., 1989. Nanocapsule formation by interfacial deposition following solvent displacement. *Int. J. Pharm.* 55, R1-R4.
- Franco M., Trapani G., Latrofa A., Tullio C., Provenzano M.R., Serra M., Muggironi M., Biggio G., Liso G., 2001. Dissolution properties and anticonvulsant activity of phenytoin polyethylene glycol 6000 and polyvinylpyrrolidone K-30 solid dispersions. *Int. J. Pharm.* 225, 63-73.
- Fukushima M., Inaba Y., Kobari S., Morishita M., 1975. 3,891,570.

## **G**

- Galindo-Rodriguez S., Allemann E., Fessi H., Doelker E., 2004. Physicochemical parameters associated with nanoparticle formulation in the salting-out,

emulsification-diffusion, and nanoprecipitation methods. *Pharm. Res.* 21(8), 1428-1439.

Galindo-Rodriguez S.A., 2004. Etude comparative de trois techniques de préparation de nanoparticules á base de polymères: Physico-chimie, efficacité d'encapsulation et transposition d'échelle. These. University of Geneva.

Gander B., Ventouras K., Gurny R., Doelker E., 1985. In vitro dissolution medium with supramicellar surfactant concentration and its relevance for in vivo absorption. *Int. J. Pharm.* 27, 117-124.

Ganguly S., Dash A.K., 2004. A novel in situ gel for sustained drug delivery and targeting. *Int. J. Pharm.* 276(1-2), 83-92.

Gershanik T., Benita S., 1996. Positively charged self-emulsifying oil formulation for improving oral bioavailability of progesterone. *Pharm. Dev. Technol.* 1(2), 147-157.

Gershanik T., Benita S., 2000. Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs. *Eur. J. Pharm. Biopharm.* 50, 179-188.

Gershanik T., Benzeno S., Benita S., 1998. Interaction of the self-emulsifying lipid drug delivery system with mucosa of everted rat intestine as a function of surface charge and droplet size. *Pharm. Res.* 15, 863-869.

Gopferich A., 1996. Polymer degradation and erosion: mechanisms and application. *Eur. J. Pharm. Biopharm.* 42(1), 1-11.

Govender T., Stolnik S., Garnett M.C., Illum L., Davis S.S., 1999. PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. *J. Control. Rel.* 57 (2), 171-185.

Graham P.D., Brodbeck K.J., McHugh A.J., 1999. Phase inversion dynamics of PLGA solutions related to drug delivery. *J. Control. Rel.* 58, 233-245.

Grizzi I., Garreau H., Li S., Vert M., 1995. Hydrolytic degradation of devices based on poly(DL-lactic acid) size dependence. *Biomaterials* 16, 305-311.

Guarini S., Ferrari W., 1985. Sodium deoxycholate promotes the absorption of heparin administered orally, probably by acting on gastrointestinal mucosa, in rats. *Experientia*, 41, 350-352.

## H

Hall S.C., Tan M.M., Leonard J.J., Stevenson C.L., 1999. Characterization and comparison of leuprolide degradation profiles in water and dimethyl sulfoxide. *J. Peptide Res.* 53, 432-441.

- Hanna M.H., York P., 1998. Method and apparatus for the formulation of particles. US Patent 5,851,453.
- Hasegawa A., Kawamura R., Nakagawa H., Sugimoto I., 1985. Physical properties of solid dispersions of poorly water-soluble drugs with enteric coating agents. *Chem. Pharm. Bull.* 33, 3429-3435.
- Hasirci V., Lewandrowski K., Gresser J.D., Wise D.L., Trantolo D.J., 2001. Versatility of biodegradable biopolymers: degradability and in vivo application. *J. Biotech.* 86, 135-150.
- Hatefi A., Amsden B., 2002. Biodegradable injectable in situ forming drug delivery systems. *J. Control. Rel.* 80, 9-28.
- Hilton J.E., Summers M.P., 1986. The effect of wetting agents on the dissolution of indomethacin solid dispersion systems. *Int. J. Pharm.* 31, 157-164.
- Hirasawa N., Ishise S., Miyata H., Danjo K., 2004. Application of nilvadipine solid dispersion to tablet formulation and manufacturing using crospovidone and methylcellulose as dispersion carriers. *Chem. Pharm. Bull.* 52, 244-247.
- Hirasawa N., Ishise S., Miyata H., Danjo K., 2003. Physicochemical characterization and drug release studies of nilvadipine solid dispersions using water-insoluble polymer as a carrier. *Drug Dev. Ind. Pharm.* 29(3), 339-344.
- Holland S.J., Tighe B.J., Gould P.L., 1986. Polymer for biodegradable medical devices. 1. The potential of polyesters as controlled macromolecular release systems. *J. Control. Rel.* 4, 155-80.
- Horisawa E., Danjo K., and Haruna M., 2000. Physical properties of solid dispersion of a nonsteroidal anti-inflammatory drug (M-5011) with Eudragit E. *Drug Dev. Ind. Pharm.* 26, 1271-1278.
- Hu J., Johnson K.P., Williams III R.O., 2004. Nanoparticle engineering processes for enhancing the dissolution rates of poorly water soluble drugs. *Drug Dev. Ind. Pharm.* 30(3), 233-245.
- Hu J., Johnston K.P., Williams R.O.I., 2003. Spray freezing into liquid (SFL) particle engineering technology to enhance dissolution of poorly water soluble drugs: organic solvent vs. aqueous-organic co-solvent systems. *Eur. J. Pharm. Sci.* 20, 295-303.
- Hu J., Rogers T.L., Brown J., Young T., Johnston K.P., Williams III R.O., 2002. Improvement of dissolution rates of poorly water soluble APIs using novel spray freezing into liquid technology. *Pharm. Res.* 19(9), 1278-1284.

Hülsmann S., Backensfeld T., Keitel S., Bodmeier R., 2000. Melt extrusion-an alternative method for enhancing the dissolution rate of 17 $\beta$ -estradiol hemihydrate. *Eur. J. Pharm. Biopharm.* 49, 237-242.

## I

ICH Topic Q 3 C. 1997. Impurities, Residual Solvents. Step 4, Consensus guideline. The European Agency for the Evaluation of Medicinal Products. Human Medicines Evaluation Unit.

Im-Emsap W., 2002. In vitro and in vivo properties of injectable biodegradable in situ forming microparticle systems. Thesis, pp 234-235.

Irie T., Uekama K., 1997. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. *J. Pharm. Sci.* 86(2), 147-62.

Ismailos G., Peppas C., Dressman J., Macheras P., 1991. Unusual solubility behavior of cyclosporine A in aqueous media. *J. Pharm. Pharmacol.* 43, 287-289.

## J

Jain R.A., Rhodes C.T., Railkar A.M., Malick A.W., Shah N.A., 2000b. Controlled release of drugs from injectable in situ formed biodegradable PLGA microsphere: effect of various formulation variables. *Eur. J. Pharm. Biopharm.* 50, 257-262.

Jain R.A., Rhodes C.T., Railkar A.M., Malick A.W., Shah N.H., 2000a. Controlled delivery of drugs from a novel injectable in situ formed biodegradable PLGA microsphere system. *J. Microencapsul.* 17(3), 343-362.

Jalil R., Nixon J.R., 1990. Biodegradable poly (lactic acid) and poly (lactide-co-glycolide) microcapsules: problems associated with preparative techniques and release properties. *J. Microencapsul.* 7, 297-325.

Jiao Y., Ubrich N., Hoffart V., Marchand-Arvier M., Vigneron C., Hoffman M., Maincent P., 2002A. Preparation and characterization of heparin-loaded polymeric microparticles. *Drug Dev. Ind. Pharm.* 8, 1033-1041.

Jiao Y., Ubrich N., Hoffart V., Marchand-Arvier M., Vigneron C., Hoffman M., Maincent P., 2002B. Anticoagulant activity of heparin following oral administration of heparin-loaded microparticles in rabbits. *J. Pharm. Sci.* 91, 1-9.

Jiao Y., Ubrich N., Hoffart V., Marchand-Arvier M., Vigneron C., Hoffman M., Maincent P., 2002C. In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits. *Circulation* 105, 230-235.

Jiao Y., Ubrich N., Marchand-Arvier M., Vigneron C., Hoffman M., Maincent P., 2001. Preparation and evaluation of heparin-loaded polymeric nanoparticles. *Drug Del.* 8,



135-141.

Jung J.Y., Yoo S.D., Lee S.H., Kim K.H., Yoon D.S., Lee K.H., 1999. Enhanced solubility and dissolution rate of itraconazole by a solid dispersion technique. *Int. J. Pharm.* 187, 209-218.

## **K**

Kachi S., Terada M., Hashimoto M., 1998. Effect of amorphous and polymorphs of PF1022A, a new antinematode drug on *angiostrongylus costaricensis* in mice. *Jpn. J. Pharmacol.* 77, 235-245.

Kasim N.A., Whitehouse M., Ramachandan C., 2003. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. *Molecular pharmaceutics.* 1, 85-96.

Katayama H., Nishimura T., Ochi S., Tsuruta Y., Yamazaki Y., Shibata K., Yoshitomi H., 1999. Sustained release liquid preparation using sodium alginate for eradication of *Helicobacter pylori*. *Biol. Pharm. Bull.* 22, 55-60.

Kawakami K., Yoshikawa T., Moroto Y., Kanaoka E., Takahashi K., Nishihara Y., Masuda K., 2002. Microemulsion formulation for enhanced absorption of lipophilic drugs. I. Prescription design. *J. Control. Rel.* 81, 65-74.

Kawasaki N., Ohkura R., Miyazaki S., Uno Y., Sugimoto S., Attwood D., 1999. Thermally reversible xyloglucan gels as vehicles for oral drug delivery. *Int. J. Pharm.* 181, 227-234.

Khalil, S. A. H., Mortada, L M., 1978. Decreased dissolution of phenylbutazone-PEG 6000 solid dispersions upon storage. *J. Drug Res.* 10(1-2), 141-50.

Khoo S.M., Porter C.J.H., Charman W.N., 2000. The formulation of Halofantrine as either non-solubilising PEG 6000 or solubilising lipid based solid dispersions: physical stability and absolute bioavailability assessment. *Int. J. Pharm.* 205, 65-78.

Kibbe A.H., Wade A., Weller P.J., 1994. *Hand Book of Pharmaceutical Excipient.* Am. Pharm. Assoc. and Pharm. Soc. GB.

Kislalioglu M.S., Khan M.A., Blount C., Goettsch R.W., Bolton S., 1991. Physical characterization and dissolution properties of ibuprofen: Eudragit coprecipitates. *J. Pharm. Sci.* 80(8), 799-804.

Kitajima M., Kondo A., Morishita M., Abe J., 1973. U.S. Patent 3,714,065.

Kobayashi P., Ito S., Itai S., Yamamoto K., 2000. Physicochemical properties and bioavailability of carbamazepine polymorphs and dehydrate. *Int. J. Pharm.* 193, 137-146.

- Koester L.S., Bertuol J.B., Groch K.R., Xavier C.R., Moellerke R., Mayorga P., Dalla Costa T., Bassani V.L., 2004. Bioavailability of carbamazepine:beta-cyclodextrin complex in beagle dogs from hydroxypropylmethylcellulose matrix tablets. *Eur. J. Pharm. Sci.* 22(2-3), 201-207.
- Kollidon, 2001. Polyvinylpyrrolidone for the pharmaceutical industry, BASF, 6<sup>th</sup> edition. pp 111 and 71
- Kranz H., Bodmeier R., 1998. A biodegradable in-situ forming system for controlled drug release. *Pharm. Sci. Suppl.* 1, 414.
- Kranz H., Brazeau G.A., Napaporn J., Martin R.L., Millard W., Bodmeier R., 2001. Myotoxicity studies of injectable biodegradable in-situ forming drug delivery systems. *Int. J. Pharm.* 212, 11-18.
- Kranz H., Ubrich N., Maincent P., Bodmeier R., 2000. Physicomechanical properties of biodegradable poly(D,L-lactide) and poly(D,L-lactide-co-glycolide) films in the dry and wet states. *J. Pharm. Sci.* 89(12), 1558-1566.
- Kubo W., Miyazaki S., Attwood D., 2003. Oral sustained delivery of paracetamol from in situ-gelling gellan and sodium alginate formulations. *Int. J. Pharm.* 258, 55-64.
- Kubo W., Miyazaki S., Dairaku M., Togashi M., Mikami R., Attwood D., 2004. Oral sustained delivery of ambroxol from in situ-gelling pectin formulations. *Int. J. Pharm.* 271, 233-240.
- L**
- Lambert W.J., Peck K.D., 1995. Development of an in situ forming biodegradable poly-lactide-co-glycolide system for the controlled release of proteins. *J. Control. Rel.* 33, 189-195.
- Lamprecht A., Yamamoto H., Takeuchi H., Kawashima Y., 2004. Design of pH-sensitive microspheres for the colonic delivery of the immunosuppressive drug tacrolimus. *Eur. J. Pharm. Biopharm.* 58, 37-43.
- Le C.P., Rytting J.H., Gajan V., Chevanne F., Le V.R, 1997. In vitro controlled release kinetics of local anaesthetics from poly (D,L-lactide) and poly(lactide-co-glycolide) microspheres. *J. Microencapsul.* 14, 243-255.
- Lee J.H., Park T.G., Choi H.K., 1999. Development of oral drug delivery system using floating microspheres. *J. Microencapsul.* 16(6), 715-729.
- Lee Y., Kim S.H., Byun Y., 2000. Oral delivery of new heparin derivatives in rats. *Pharm. Res.* 17(10), 1259-1264.
- Lee Y., Nam J.H., Shin H., Byun Y., 2001. Conjugation of low-molecular-weight heparin

- and deoxycholic acid for the development of a new oral anticoagulant agent. *Circulation* 104, 3116-3120.
- Lehmann K., 2001. Practical course in film coating of pharmaceutical dosage forms with Eudragit®. Copyright by Röhm GmbH Co. KG, Pharma Polymers, Darmstadt, Germany. pp 9.
- Leone-Bay A., Paton D.R., Variano B., Leipold H., Rivera T., Miura-Fraboni J., Baughman R., Santiago N., 1998. Acylated non-alpha-amino acids as novel agents for the oral delivery of heparin sodium USP. *J. Control. Rel.* 50, 41-49.
- Lerk C.F., In Topics in pharmaceutical sciences, Breimer D.D., Cromelin D.J.A., Midha K.K., 1989. Federation Internationale Pharmaceutique. 195-209.
- Leroux J.C., Cozens R., Roesel J.L., Galli B., Doelker E., Gurny R., 1996. pH-sensitive nanoparticles: an effective means to improve the oral delivery of HIV-1 protease inhibitors in dogs. *Pharm. Res.* 13, 485-487.
- Leroux J.C., Cozens R., Roesel J.L., Galli B., Kubel F., Doelker E., Gurny R., 1995. Pharmacokinetics of a novel HIV-1 protease inhibitor incorporated into biodegradable or enteric nanoparticles following intravenous and oral administration to mice. *J. Pharm. Sci.* 84, 1387-1391.
- Leuner C., Dressman J., 2000. Improving drug solubility for oral delivery using solid dispersion. *Eur. J. Pharm. Biopharm.* 50, 47-60.
- Lewis, D.H., 1990. Controlled release of bioactive agents from lactide/glycolide polymers. In: Biodegradable polymers as drug delivery systems. Eds: Chasin, M., Langer R., Marcel Dekker: New York, 1990, pp. 1-41.
- Lieberman H.A., Rieger M.M., Banker G.S., 1988. Pharmaceutical dosage forms, Disperse systems, volume 1, Marcel Dekker, Inc, New York and Basel.
- Lindholm A., Henricsson S., Lind M., Dahlqvist R., 1988. Intraindividual variability in the relative systemic availability of cyclosporin after oral dosing. *Eur. J. Clin. Pharmacol.* 34, 461-464.
- Lipinski C., 2002. Poor aqueous solubility-an industry wide problem in drug delivery. *Am. Pharm. Rev.* 5, 82-85.
- Lo W.Y., Law S.L., 1996. Dissolution behavior of griseofulvin solid dispersions using polyethylene glycol, talc, and their combination as dispersion carriers. *Drug Dev. Ind. Pharm.* 22, 231-236.
- Löbenberg R., Amidon G. L., 2000. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international

regulatory standards. *Eur. J. Pharm. Biopharm.* 50, 3-12.

Loftsson T., Brewster M.E., 1996. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. *J. Pharm. Sci.* 85, 1017-1025.

López Esguerra V., 2005. Biodegradable implants and in situ forming systems. Thesis, Freie Universität Berlin.

## M

Malkov D., Wang H., Dinh S., Gomez-Orellana I., 2002. Pathway of oral absorption of heparin with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate. *Pharm. Res.* 19(8), 1180-1184.

Maloy K.J., Donachie A.M., O'Hagan D.T., Mowat A.M., 1994. Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles. *Immunology* 81(4), 661-667.

Mandal T.K., Bostanian L.A., Graves R.A., Chanpman S.R., Womack I., 2002. Development of biodegradable microcapsules as carrier for oral controlled delivery of amifostine. *Drug Dev. Ind. Pharm.* 28(3), 339-344.

Martin A, 1993. *Physical pharmacy*. 4<sup>th</sup> edition. Lea and Febiger, Philadelphia, London, pp 299.

Mason N.S., Miles C.S., Sparks R.E., 1981. Hydrolytic degradation of poly D,L-(lactide). In: C.G. Gebelein, F.F. Kblitz, editors. *Biomedical and dental application of polymers*. New York: Plenum Press, 279-291.

Matsunami Y., Ichikawa, 2002. Characterization of the structure of poly(urea-urethane) microcapsules. *Int. J. Pharm.* 242, 147-153.

Maulding H.V., Tice T.R., Cowsar D.R., Fong J.W., Pearson J.E., Nazareno J.P., 1986. Biodegradable microcapsules: acceleration of polymeric excipient hydrolytic rate by incorporation of a basic medicament. *J. Control. Rel.* 3, 103-117.

McClellan S., Prosser E., Meehan E., O'Malley D., Clarke N., Ramtoola Z., Brayden D., 1998. Binding and uptake of biodegradable poly-DL-lactide micro- and nanoparticles in intestinal epithelia. *Eur. J. Pharm. Sci.* 6(2), 153-163.

McGinity J.W., 1997. *Aqueous polymeric coatings for pharmaceutical dosage forms*. Marcel Dekker Inc., New York, pp. 385-418.

Menei P., Daniel V., Montero-Menei C., Brouillard M., Pouplard B.A., Benoit J.P., 1993. Biodegradation and brain tissue reaction to poly(lactide-co-glycolide) microspheres. *Biomaterials* 14, 470-478.

Merisko-Liversidge E., Liversidge G.G., Cooper E.R., 2003. Nanosizing: a formulation

- approach for poorly-water-soluble compounds. *Eur. J. Pharm. Sci.* 18, 113-120.
- Miyazaki S., Aoyama H., Kawasaki N., Kubo W., Attwood D., 1999. In situ-gelling gellan formulations as vehicles for oral drug delivery. *J. Control. Rel.* 60, 287-295.
- Miyazaki S., Endo K., Kawasaki N., Kubo W., Watanabe H., Attwood D., 2003. Oral sustained delivery of paracetamol from in situ gelling xyloglucan formulations. *Drug Dev. Ind. Pharm.* 29(2), 113-119.
- Miyazaki S., Kawasaki N., Kubo W., Endo K., Attwood D., 2001. Comparison of in situ gelling formulations for the oral delivery of cimetidine. *Int. J. Pharm.* 220, 161-168.
- Mohr D., Wolff M., Kissel T., Gamma irradiation for terminal sterilization of 17 $\beta$ -estradiol loaded poly-(D,L-lactide-co-glycolide) microparticles. *J. Control. Rel.* 61, 203-217.
- Montanari L., Costantini M., Signoretti E.C., Valvo L., Santucci M., Bartolomei M., Fattibene P., Onori S., Faucitano A., Conti B., Genta I., 1998. Gamma irradiation effects on poly(DL-lactide-co-glycolide) microspheres. *J. Control. Rel.* 56, 219-229.
- Morfex information, Morflex Inc., Greensboro, NC, USA, 2001.
- Morishita I., Morishita M., Machida Y., Nagai T., 1991. Controlled release microspheres based on Eudragit L100 for the oral administration of erythromycin. *Drug Des. Deliv.* 7(4), 309-319.
- Morita T., Horikiri Y., Suzuki T., Yoshino H., 2001. Applicability of various amphiphilic polymers to the modification of protein release kinetics from biodegradable reservoir-type microspheres. *Eur. J. Pharm. Biopharm.* 51, 45-53.
- Morton A.K., Edwards H.E., Allen J.C., Philipps G.O., 1981. An evaluation of the oral administration of commercial and fractionated samples in rats. *Int. J. Pharm.* 9, 321-335.
- Müller R.H., Jacobs C., Kayser O., 2001. Nanosuspensions as particulate drug formulations in therapy rationale for development and what we can expect for the future. *Adv. Drug Deliv. Rev.* 54, 131-155.
- Muranishi S., Tokunaga Y., Taniguchi K., Sezaki H., 1977. Potential absorption of heparin from the small intestine and the large intestine in the presence of monoolein mixed micelles. *Chem. Pharm. Bull.* 25(5), 1159-1161.

## N

- Nagasawa K., Nakanishi H., Yamamoto R., Kintsuji S., Fujimoto S., 2002. Decreased bioavailability of carbamazepine suppository after its intrarectal and

intracolostomal administration to rectal-resected or colostoma-constructed rabbits.  
*Int. J. Pharm.* 241, 375-384.

Nazzal S., Guven N., Reddy I.K., Khan M.A., 2002. Preparation and characterization of coenzyme Q<sub>10</sub>-Eudragit solid dispersion. *Drug Dev. Ind. Pharm.* 28(1), 49-57.

## O

O'Donnell P. B., McGinity J.W., 1998. Influence of processing on the stability and release properties of biodegradable microspheres containing thioridazine hydrochloride. *Eur. J. Pharm. Biopharm.* 45, 83-94.

Okada H., 1997. One- and three-month release injectable microspheres of the LH-RH superagonist leuporelin acetate. *Adv. Drug Deliv. Rev.* 28, 43-70.

Okumu F.W., Dao L. N., Fielder P.J., Dybdal N., Brooks D., Sane S., Cleland J.L., 2002. Sustained delivery of human growth hormone from a novel gel system: SABER™. *Biomaterials* 23, 4353-4358.

Ozturk S.S., Palsson B.O., Donohoe B., Dressman J.B., 1988. Kinetics of release from enteric-coated tablets. *Pharm. Res.* 5(9), 550-565.

## P

Pace G.W., Vachon M.G., Mishra A.K., Henrikson I.B., Krukonis V., 2001. Processes to generate submicron particles of water-insoluble compounds. US Patent 6,177,103.

Packhaeuser C.B., Schnieders J., Oster C.G., Kissel T., 2004. In situ forming parenteral drug delivery systems: an overview. *Eur. J. Pharm. Biopharm.* 58, 445-455.

Paradkar A., Ambike A.A., Jadhav B.K., Mahadik K.R., 2004. Characterization of curcumin-PVP solid dispersion obtained by spray drying. *Int. J. Pharm.* 271(1-2), 281-286.

Park, T.G., 1995. Degradation of poly(lactic-co-glycolic acid) microspheres: effect of copolymer composition. *Biomaterials* 16, 1123-1130.

Petereit H., Weisbrod W., 1999. Formulation and process considerations affecting the stability of solid dosage forms formulated with methacrylate copolymers. *Eur. J. Pharm. Biopharm.* 47, 15-25.

Pharmacy Today. An official publication of the American Pharmaceutical Association 5, 10.

Pikal M.J., Shah S., Roy M.L., Putman R., 1990. The secondary drying stage of freeze drying: drying kinetics as a function of temperature and chamber pressure. *Int. J. Pharm.* 60, 203-217.

Pineo G.F., Hull R.D., Marder V.J., 2001. Orally active heparin and low molecular

weight heparin. *Curr. Opin. Pulm. Med.* 7, 344-348.

Pinnamaneni S., Das N. G., and Das S. K., 2002. Formulation approaches for orally administered lipophilic drugs. *Pharmazie* 57, 291-300.

Polakovic M., Gorner T., Gref R., Dellacherie E., 1999. Lidocaine loaded biodegradable nanospheres. II. Modelling of drug release. *J. Control. Rel.* 60, 169-177.

## **R**

Radomsky M.L., Brouwer G., Floy B.J., Loury D.J., Chu F., Tipton A.J., Sanders L.M., 1993. The controlled release of Ganirelix from the Atrigel injectable implant system. *Proc. Intern. Symp. Control. Rel. Bioact. Mater.* 20.

Radtke M., 2001. Pure drug nanoparticles for the formulation of lipophilic drugs. *New drugs* 3, 62-68.

Rajewski, R.A., Stella, V.J., 1996. Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. *J. Pharm. Sci.* 85, 1142-1169.

Ran Y., Zhao L., Xu Q., Yalkowsky S. H., 2001. Solubilization of cyclosporine A. *AAPS PharmSciTech.* 2(1), article 2.

Ravivarapu H.B., Moyer K.L., Dunn R.L., 2000. Parameters affecting the efficacy of a sustained release polymeric implant of leuprolide. *Int. J. Pharm.* 194, 181-191.

Reed A.M., Gilding D.K., 1981. Biodegradable polymers for use in surgery-poly(glycolic)/poly(lactic acid) homo and copolymers: 2. In vitro degradation. *Polymer* 22, 494-498.

Ritschel W.A., *Handbook of Basic Pharmacokinetics*, 2d ed., 1980. Drug Intelligence Publications, Hamilton, Ill., pp. 71.

Roger T.L., Nelsen A.C., Sarkari M., Young T., Johnston K.P., Williams R.O., 2003. Enhanced aqueous dissolution of a poorly water soluble drug by novel particle engineering technology: spray-freezing into liquid with atmosphere freeze-drying. *Pharm. Res.* 20, 485-493.

Rogers B., Eroschenko-Styer K., 2001. Analysis of the delivery of an oral heparin formulation. *PSCI 425*. <http://otc.isu.edu/~das/Presentations-2001-pdf/Heparin.pdf>.

Rogers T. L., Nelsen A. C., Hu J., Brown J. N., and Williams III R. O., 2002. A novel particle engineering technology to enhance dissolution of poorly water soluble drugs: spray-freezing into liquid. *Eur. J. Pharm. Biopharm.* 54, 271-280.

Rogers T.L., Hu J., Yu Z., Johnston K.P., Williams III R.O., 2002. A novel particle engineering technology: spray-freezing into liquid. *Int. J. Pharm.* 242, 93-100.

Ross P.D., Rekharsky M.V., 1996. Thermodynamics of hydrogen bond and hydrophobic

interactions in cyclodextrin complexes. *Biophys. J.* 71, 2144-2154.

## S

Saarinen-Savolainen P., Jävinen T., Taipale H., Urtti A., 1997. Method for evaluating drug release from liposomes in sink conditions. *Int. J. Pharm.* 159, 27-33.

Santos Magalhaes N.S., Fessi H., Puisieux F., Benita S., Seiller M., 1995. An in vitro release kinetic examination and comparative evaluation between submicron emulsion and polylactic acid nanocapsules of clofibrade. *J. Microencapsul.* 12(2), 195-205.

Schmitt E.A., Flanagan D.R., Linhardt R. J., 1994. Importance of distinct water environments in the hydrolysis of poly(DL-lactide-co-glycolide). *Macromolecules* 27, 743-748.

Schwach-Abdellaoui K., Monti A., Heller J., Gurny R., 2001. Optimization of a novel bioerodible device based on auto-catalyzed poly(ortho esters) for controlled delivery of tetracycline to periodontal pocket. *Biomaterials* 22, 1659-1666.

Sekiguchi K., Obi N., 1961. Studies on absorption of eutectic mixture. I. A comparison of the behavior of eutectic mixture of sulfathiazole and that of ordinary sulfathiazole in man. *Chem. Pharm. Bull.* 9, 866-872.

Serajuddin A.T.M., 1999. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. *J. Pharm. Sci.* 88 (10), 1058-1066.

Shah N.H., Carvajal M.T., Patel C.I., Infeld M.H., Malick A.W., 1994. Self-emulsifying drug delivery systems (SEDDS) with polyglycolized glycerides for improving in vitro dissolution and oral absorption of lipophilic drugs. *Int. J. Pharm.* 106, 15-23.

Shah N.H., Railkar A.S., Chen F.C., Tarantino R., Kumar S., Murjani M., Palmer D., Infeld M.H., Malick A.W., 1993. A biodegradable injectable implant for delivering micro and macromolecules using poly (lactic-co-glycolic) acid (PLGA) copolymers. *J. Control. Rel.* 27, 139-147.

Sinha V.R., Trehan A., 2003. Biodegradable microspheres for protein delivery. *J. Control. Rel.* 90, 261-280.

Sridevi S., Chauhan A.S., Chalasani K.B., Jain A.K., Diwan P.V., 2003. Enhancement of dissolution and oral bioavailability of gliquidone with hydroxyl propyl-beta-cyclodextrin. *Pharmazie* 58(11), 807-810.

Stevenson C.L., Leonard J.J., Hall S.C., 1999. Effect of peptide concentration and temperature on leuprolide stability in dimethyl sulfoxide. *Int. J. Pharm.* 191, 115-129.



Strickley R.G., 2004. Solubilizing excipients in oral and injectable formulations. *Pharm. Res.* 21, 201-230.

Subramaniam B., Rajewski R.A., Snavely K., 1997A. Pharmaceutical processing with supercritical carbon dioxide. *J. Pharm. Sci.* 86, 885-890.

Subramaniam B., Saim S., Rajewski R.A., Stella V., 1997B. Method of particle precipitation and coating using nearcritical and supercritical antisolvents. US Patent 5,833,891.

Sullivan S.A., Yarbrough J.C., Fengl R.W., Tipton A.J., Gibson J.W., 1998. Sustained release of orally administered active using SABER delivery system incorporated into soft gelatin capsules. *Proc. Int. Symp. Contr. Rel. Bioact. Mater.* 25, pp 918-919.

Szejtli, J., 1988. *Cyclodextrin Technology*. Kluwer Academic, Dordrecht.

Szejtli, J., 1990. The cyclodextrins and their applications in biotechnology. *Carbohydr. Polym.* 12, 375-392.

## T

Takada K., Oh-hashii M., Furuya Y., Yoshikawa H., Muranishi S., 1989. Enteric solid dispersion of ciclosporin A (CiA) having potential to deliver CiA into lymphatics. *Chem. Pharm. Bull.* 37(2), 471-474.

Taniguchi K., Muranishi S., Sezaki H., 1980. Enhanced intestinal permeability to macromolecules. II. Improvement of the large intestinal absorption of heparin by lipid-surfactant mixed micelles in rats. *Int. J. Pharm.* 4, 219-228.

Tarr B.D., Yalkowsky S.H., 1989. Enhanced intestinal absorption of cyclosporine in rats through the reduction of emulsion droplet size. *Pharm. Res.* 6, 40-43.

Taylor L.S., Zografi G., 1997. Spectroscopic characterization of interaction between PVP and indomethacin in amorphous molecular dispersions. *Pharm. Res.* 14, 1691-1698.

Terhaag B., Richter K., Diettrich H., 1978. Concentration behavior of carbamazepine in bile and plasma of man. *Int. J. Clin. Pharm. Biopharm.* 16(12), 607-609.

Thanou M., Coos Verhoef J., Nihot M., Verheijden J.H.M., Junginger H.E., 2001A. Enhancement of the intestinal absorption of low molecular weight heparin (LMWH) in rats and pigs using Carbopol<sup>®</sup> 934P. *Pharm. Res.* 18(11), 1638-1641.

Thanou M., Nihot M., Jansen M., Verhoef J.C., Junginger H.E., 2001B. Mono-N-carboxymethyl chitosan (MCC), a polyampholytic chitosan derivative, enhances the intestinal absorption of low molecular weight heparin across intestinal epithelia in vitro and in vivo. *J. Pharm. Sci.* 90(1), 38-46.

Thompson, D.O., 1997. Cyclodextrins, enabling excipients: their present and future use in pharmaceuticals. *Crit. Rev. Therap. Drug Carrier Syst.* 14, 1-104.

Tipton A.J., Fujita S.M., 1991. A biodegradable, injectable delivery system for nonsteroidal anti-inflammatory drugs. *Pharm. Res.* 9, S-196.

Tracy M.A., Ward K.L., Firouzabadian L., Wang Y., Dong N., Qian R., Zhang Y., 1999. Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro. *Biomaterials* 20, 1057-1062.

## U

Urata T., Arimori K., Nakano M., 1999. Modification of release rate of cyclosporin A from poly(L-lactic acid) microspheres by fatty acid esters and in-vivo evaluation of the microspheres. *J. Control. Rel.* 58, 133-141.

## V

Van de Weerk M., Hennink W.E., Jiskoot W., 2000. Protein instability in poly(lactic-co-glycolic acid) microparticles. *Pharm. Res.* 17, 1159-1167.

Van Helden, S.P., 1992. Structure and stability of cyclodextrin complexes: a molecular modeling study. Ph.D. Thesis, Faculty of Pharmacy, Utrecht University, The Netherlands.

Vert M., Li S., Garreau H., 1992. New insights on the degradation of bioresorbable polymeric devices based on lactic and glycolic acids. *Clin. Mater.* 10(1-2), 3-8.

Vert M., Mauduit J., Li S., 1994. Biodegradation of PLA/GA polymers: increasing complexity. *Biomaterials* 15(15), 1209-1213.

Vila Jato J. L., Blanco J., Martinez R., Concheiro, A., 1984. Aging of solid dispersions: effects on bioavailability of acetaminophen-polyethylene glycol 20,000 system. *Biopharm. Pharmacokinet. Eur. Congr.* 2nd, 1, 353-9.

Vippagunta, S.R., Brittain, H.G., Grant, D.J., 2001. Crystalline solids. *Adv. Drug Del. Rev.* 48, 3-26.

Von Burkersroda F., Schedl L., Göpferich A., 2002. Why degradable polymers undergo surface erosion or bulk erosion. *Biomaterials* 23, 4221-4231.

## W

Wade A., Weller P.J., 1993. Handbook of pharmaceutical excipients. 534-5, 540-1.

Wakayama N., Juni K., Nakano M., 1982. Influence of physicochemical properties of polylactic acid on the characteristics and in vitro release patterns of polylactic acid microspheres containing local anesthetics. *Chem. Pharm. Bull.* 30, 2621-2628.

Wakiyama N., Juni K., Nakano M., 1981. Preparation and evaluation in vitro of polylactic

- acid microspheres containing local anesthetics. *Chem. Pharm. Bull.* 29, 3363-3368.
- Wakiyama N., Juni K., Nakano M., 1982. Preparation and evaluation in vitro and in vivo of polylactic acid microsphere containing dibucaine. *Chem. Pharm. Bull.* 30, 3719-3727.
- Wang L., Kleiner L., Venkatraman S., 2003. Structure formation in injectable poly (lactide-co-glycolide) depots. *J. Control. Rel.* 90, 345-354.
- Wells J.I., 1988. *Pharmaceutical preformulation: The physicochemical properties of drug substances*; Ellis Horwood Limited: Chichester, England, pp 227.
- Williams R.Q., Hu J., Rogers T.L., Barron M.K., Young T.J., Yu Z., Johnston K.P., 2003. Process for production of nanoparticles and microparticles by spray freezing into liquid. US Patent 20030041602.
- Woo B.H., Kostanski J.W., Gebrekidan S., Dani B.A., Thanoo B.C., DeLuka P.P., 2001. Preparation, characterization and in vivo evaluation of 120-day poly(D,L-lactide) leuprolide microspheres. *J. Control. Rel.* 75, 307-315.

## Y

- York P., 1999. Strategies for particle design using supercritical fluid technologies. *PSTT* 2, 430-440.
- Young T.J., Mawson S., Johnston K.P., Henriksen I.B., Pace G.W., Mishra A.K., 2000. Rapid expansion from supercritical to aqueous solution to produce submicron suspensions of water-insoluble drugs. *Biotechnol. Prog.* 16, 402-407.

## Z

- Zaghloul A.A., Faltinek J., Vaithiyalingam S.R., Reddy I.K., Khan M.A., 2001B. Naproxen-Eudragit microspheres: screening of process and formulation variable for the preparation of extended release tablets. *Pharmazie* 56, 321-324.
- Zaghloul A.A., Vaithiyalingam S.R., Faltinek J., Reddy I.K., Khan M.A., 2001A. Response surface methodology to obtain naproxen controlled release tablets from its microspheres with Eudragit L100-55. *J. Microencapsul.* 18(5), 651-662.
- Zaks A., Klibanov A.M., 1988. The effect of water on enzyme action in organic media. *J. Biol. Chem.* 263, 3194-3201.
- Zerrouk N., Chemtob C., Arnaud P., Toscani S., Dugue J., 2001. In vitro and in vivo evaluation of carbamazepine-PEG 6000 solid dispersions. *Int. J. Pharm.* 225, 49-62.
- Zhang M.L., Zhang J.H., Wang H.T., Yin Y.P., Yu Z.C., 1997. Pharmacokinetics of carbamazepine at different doses. *Zhongguo Yiyuan Yaoxue Zazhi* 17(6), 243-245.